Statement: Study finds genital herpes vaccine ineffective in women
2010-10-01
(Press-News.org) An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.
The Phase 3 trial, sponsored by GlaxoSmithKline (GSK) Biologicals, based in Belgium, with support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, began in 2002. A total of 8,323 women aged 18-30 years participated in the trial at 50 sites in the United States and Canada. At the time of their enrollment, the study participants were free of the two types of herpes simplex viruses (HSV), HSV-1 and HSV-2.
Participants in the Herpevac trial were randomly divided into two groups. One group received the candidate vaccine, containing HSV protein along with an adjuvant intended to boost immune responses. The second, control group received a version of Havrix, a licensed vaccine against hepatitis A. This study design gave all participants the potential opportunity to be protected against either genital herpes or hepatitis A. GSK developed the candidate vaccine and also manufactures Havrix.
Each volunteer was vaccinated at the beginning of the study and again one and six months later. The participants were followed for 20 months after the initial injection and evaluated at each visit for HSV infection and genital herpes disease.
In two earlier studies involving men and women who did not have genital herpes but whose sexual partners were known to be infected, the candidate vaccine prevented genital herpes disease in more than 70 percent of the female volunteers who were free of HSV-1 and HSV-2 but had no clear effect in men. These studies formed the basis to conduct the larger Herpevac study in women only.
In the Herpevac study, however, the investigational vaccine was ineffective in protecting against genital herpes disease. The estimate of vaccine effectiveness was 20 percent, but all estimates have statistical uncertainty, and this effect was not substantially different from zero.
It is not known at this time why the vaccine proved ineffective, but the study collaborators continue to evaluate the trial data and intend to provide a more detailed analysis at a later date.
All the study investigators have been informed of the results. Study participants are being notified as to which vaccine they received, and those volunteers who received the candidate herpes vaccine are being offered Havrix.
HSV-1 and HSV-2, which cause cold sores and genital herpes disease, may be transmitted through sexual or other skin-to-skin contact, and can be spread even when the infected individual shows no symptoms. HSV can cause severe illness in infants born to HSV-infected women, and the virus has been identified as a risk factor for HIV transmission in adults. An estimated 1 in 4 women in the United States has genital herpes.
INFORMATION:
For additional information about the Herpevac study, please see Questions and Answers: The NIH-supported Herpevac trial for women http://www.niaid.nih.gov/news/QA/pages/HerpevacQA.aspx, and the GSK website: www.gsk.com/media/index.htm.
Media inquiries can be directed to the NIAID Office of Communications at 301-402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
ELSE PRESS RELEASES FROM THIS DATE:
2010-10-01
The landmark breast cancer screening study of women 40-49, published online in Cancer, has proven that annual mammography screening of women in their 40s reduces the breast cancer death rate in these women by nearly 30 percent. The results of this largest study ever conducted on women in this age group confirm that the use of the age of 50 as a threshold for breast cancer screening is scientifically unfounded. Women should begin getting annual mammograms at age 40.
"This study, which looked at the performance of screening mammography as it is actually used, rather than ...
2010-10-01
Characteristics such as patient engagement, physician communication, and staff coordination may help to explain why some dialysis centers achieve higher patient survival rates than others, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).
"The purpose of this study was simple: to figure out what top-performing dialysis units might be doing differently from bottom-performing units, and to translate those findings into a blueprint for action," comments Brennan M.R. Spiegel, MD, MSHS (VA Greater Los ...
2010-10-01
BOSTON –By creating a "map" of histone modifications in fat cells, investigators have discovered two new factors that regulate fat formation, a key step on the road to better understanding obesity, diabetes and other metabolic disorders. Led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and the Broad Institute, the study appears in the October 1 issue of the journal Cell.
"These findings help to demonstrate the power of epigenomic mapping when it comes to gleaning key insights into fat cell formation," explains senior author Evan Rosen, MD, PhD, an ...
2010-10-01
People with impaired kidney function are at a higher risk of future stroke than people with normal kidney function, concludes a study published on bmj.com today.
A second study, also published today, finds that even the earliest stages of chronic kidney disease are linked to a higher risk of coronary heart disease.
This study suggests that considering signs of early kidney disease, in addition to routinely measured risk factors such as blood pressure and blood cholesterol, modestly improves the identification of people at high risk of cardiovascular disease. It provides ...
2010-10-01
A strategy to encourage single embryo transfer after in vitro fertilisation (IVF) could be an important tool to prevent multiple pregnancies and their associated complications, finds a study published on bmj.com today.
Deciding how many embryos should be transferred after IVF is a complex problem. The transfer of only one embryo will prevent a multiple pregnancy and the risk of complications for mother and baby, but could require more cycles to achieve pregnancy.
Although professionals and policy makers have launched initiatives to encourage the use of single embryo ...
2010-10-01
Drug companies have not only sponsored the science of a new condition known as female sexual dysfunction, they have helped to construct it, in order to build global markets for new drugs, reveals an article in this week's BMJ.
Researching his new book 'Sex, Lies and Pharmaceuticals' Ray Moynihan, journalist and lecturer at the University of Newcastle in Australia, discovered that drug industry employees have worked with paid key opinion leaders to help develop the disease entity; they have run surveys to portray it as widespread; and they helped design diagnostic tools ...
2010-10-01
Should athletes have to undergo mandatory electrocardiographic screening (also known as ECG or heart trace) before competing? Doctors debate the issue in this week's BMJ.
Antonio Pelliccia and Domenico Corrado argue that screening athletes for "silent" heart problems would save lives. They say the best evidence of the efficacy of ECG screening on mortality in athletes comes from Italy, the only country where it is required by law, and where a mass screening programme has been in place for almost 30 years.
The incidence of sudden deaths before and after implementation ...
2010-10-01
Kathleen Alexander, associate professor of wildlife in Virginia Tech's College of Natural Resources and Environment, has discovered a novel tuberculosis (TB) species in the Mycobacterium tuberculosis complex, a group of pathogens that have adapted by using mammals as hosts. It has been nearly two decades since a new organism was identified in this group; the majority were discovered in the early and mid 20th century.
Tuberculosis is presently the leading cause of death from infectious disease, infecting more than a third of the world's population.
Alexander discovered ...
2010-10-01
Therapeutic lentiviral vectors are emerging as vital tools for molecular medicine as evidenced by the growing number of clinical trials using these vector systems. From a basic research standpoint, lentiviral vectors are very intriguing substrates. On the one hand, the HIV-1 genome offers expanded cloning capacity and the capability to transduce nondividing cells such as hematopoietic stem cells (HSCs) and neurons. However, concerns associated with the potential risk of generating replication competent lentiviral particles require the removal of significant portions ...
2010-10-01
The unusual "knot" in the bright, narrow ribbon of neutral atoms emanating in from the boundary between our solar system and interstellar space appears to have "untied," according to a paper published online in the Journal of Geophysical Research.
Researchers believe the ribbon, first revealed in maps produced by NASA's Interstellar Boundary Explorer (IBEX) spacecraft, forms in response to interactions between interstellar space and the heliosphere, the protective bubble in which the Earth and other planets reside. Sensitive neutral atom detectors aboard IBEX produce ...
LAST 30 PRESS RELEASES:
[Press-News.org] Statement: Study finds genital herpes vaccine ineffective in women
